[HTML][HTML] Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma
The Journal of clinical investigation, 2021•Am Soc Clin Investig
Glioblastoma (GBM), the most common and lethal primary brain tumor, with a median
survival rate of only 15 months, remains incurable despite intensive multimodal treatment of
surgical resection, radio-chemotherapy, and antiangiogenic therapy with bevacizumab (1–
3). While immunotherapies have been highly effective against some types of cancer, the
disappointing results of clinical trials for GBM immunotherapy represent continued
challenges (4, 5). Therefore, effective therapies for patients with GBM are urgently needed.
survival rate of only 15 months, remains incurable despite intensive multimodal treatment of
surgical resection, radio-chemotherapy, and antiangiogenic therapy with bevacizumab (1–
3). While immunotherapies have been highly effective against some types of cancer, the
disappointing results of clinical trials for GBM immunotherapy represent continued
challenges (4, 5). Therefore, effective therapies for patients with GBM are urgently needed.
Glioblastoma (GBM), the most common and lethal primary brain tumor, with a median survival rate of only 15 months, remains incurable despite intensive multimodal treatment of surgical resection, radio-chemotherapy, and antiangiogenic therapy with bevacizumab (1–3). While immunotherapies have been highly effective against some types of cancer, the disappointing results of clinical trials for GBM immunotherapy represent continued challenges (4, 5). Therefore, effective therapies for patients with GBM are urgently needed.
The Journal of Clinical Investigation